COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00035334
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : February 14, 2006
FDA Office of Orphan Products Development
Information provided by:
Bellus Health Inc

No Study Results Posted on for this Study
Recruitment Status : Completed
Primary Completion Date : No date given
Study Completion Date : December 2004
Safety, Tolerability and Pharmacokinetic Profile of FibrillexTM (Anti-AA Amyloid Agent) in Healthy and Renal Impaired Subjects. Garceau D., Gurbindo C., Laurin J. Neurochem Inc. Reference: Proceedings from the IXth International Symposium on Amyloidosis , 2001 (Budapest, Hungary)

Publications automatically indexed to this study by Identifier (NCT Number):